Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07574489 · ClinicalTrials.gov registry record · Phase 2
Whole Versus Partial Gland Boost During Prostate SBRT
A Phase 2 study, sponsored by University of Nebraska.
- Not yet
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
NCT07574489: Clinical Trial Phase 2 study, sponsored by University of Nebraska.
NCT07574489 is a Phase 2 study that has not yet begun recruiting, run by University of Nebraska. The registered enrollment target is 186 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07574489, a Phase 2 study, has not yet begun recruiting, sponsored by University of Nebraska.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
Study Summary
This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.
Primary Outcome
Cumulative incidence of grade 2 or higher chronic genitourinary (GU) toxicities assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Interventions
- RADIATION Prostate stereotactic body radiotherapy with whole gland boost
- RADIATION Prostate stereotactic body radiotherapy with DIL boost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2026-07-25 |
| Est. Completion | 2035-08-25 |
| Phase | Phase 2 |
What is known before NCT07574489 opens enrollment
NCT07574489 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% higher).
The record links to 0 conditions, and to 2 interventions - of which Prostate stereotactic body radiotherapy with whole gland boost is the first listed.
NCT07574489 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07574489 about?
NCT07574489 is a clinical study titled "Whole Versus Partial Gland Boost During Prostate SBRT". This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.
What is the current status of trial NCT07574489?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2026-07-25. Estimated completion is 2035-08-25.
What interventions are being tested in trial NCT07574489?
The interventions under investigation include: Prostate stereotactic body radiotherapy with whole gland boost (RADIATION), Prostate stereotactic body radiotherapy with DIL boost (RADIATION).
Who is sponsoring clinical trial NCT07574489?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07574489's enrollment target sits among peer trials
186 357th of 2000 higher than 1,644 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI